Literature DB >> 17245596

Changes in pelvic and systemic platinum concentrations during negative-balance isolated pelvic perfusion: correlation between platinum concentration and method of administration in a pig model.

Satoru Murata1, Hiroyuki Tajima, Yutaka Abe, Shiro Onozawa, Fumio Uchiyama, Hiromitsu Hayashi, Ryoji Kimata, Kazuhiro Nomura.   

Abstract

PURPOSE: To assess the effect of altering the method of administration during negative-balance isolated pelvic perfusion (NIPP) on the platinum concentration in the pelvic or systemic circulation.
METHODS: Twenty female pigs were used in this study. The abdominal aorta and the infra-renal vena cava were occluded with two balloon catheters and blood in the extracorporeal circuit was circulated with twin rotary pumps. NIPP was then performed with cisplatin (5 mg/kg) in 15 pigs. Three types of NIPP administration method (group A: 1 bolus, B: 2 same doses boluses, C: 3 same doses boluses) were used, five pigs being subjected to each treatment. The remaining five pigs were administered cisplatin systemically as a control study (group D). The platinum concentrations in the pelvic and systemic circulation were measured and compared.
RESULTS: (1) Pelvic circulation: There was a tendency for the platinum concentration to increase as the bolus time decreased. The platinum concentration in groups A and B was significantly (P < 0.05) higher than that in group C. Significant differences (P < 0.05) between groups A and B until 10 min after the start of NIPP. (2) Systemic circulation: Significant differences (P < 0.05) were observed between NIPP groups and D during NIPP. The platinum concentration in group D was five times higher than that in group C. (3) Plasma pelvic to systemic exposure ratio: there were no significant differences among the three NIPP groups.
CONCLUSIONS: The platinum concentrations in the pelvic and systemic circulation increased as the bolus time decreased. The plasma pelvic to systemic exposure ratio was not influenced by bolus time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245596     DOI: 10.1007/s00432-006-0168-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  16 in total

1.  Regional chemotherapy for cancer: experiences with 116 perfusions.

Authors:  J S STEHLIN; R L CLARK; E C WHITE; J L SMITH; A C GRIFFIN; R H JESSE; J E HEALEY
Journal:  Ann Surg       Date:  1960-04       Impact factor: 12.969

2.  Regional perfusion of the pelvis: consideration of the "leakage" problem.

Authors:  W LAWRENCE; P KUEHN; S MORI; J W POPPELL; B CLARKSON
Journal:  Surgery       Date:  1961-07       Impact factor: 3.982

3.  Treatment of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents.

Authors:  W G AUSTEN; A P MONACO; G S RICHARDSON; W H BAKER; R S SHAW; J W RAKER
Journal:  N Engl J Med       Date:  1959-11-19       Impact factor: 91.245

4.  Isolated pelvic perfusion: plasma pharmacokinetics depend primarily on drug dosage and not the type of drug.

Authors:  James F Belliveau; Elisabeth Arevalo; Hank Griffin; Harold J Wanebo
Journal:  Cancer Chemother Pharmacol       Date:  2005-01-15       Impact factor: 3.333

5.  Pharmacologic rationale for regional drug delivery.

Authors:  J M Collins
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

6.  A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion.

Authors:  H J Wanebo; J F Belliveau
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model.

Authors:  Satoru Murata; Hiroyuki Tajima; Gen-ichi Kusakai; Tatsuo Kumazaki; Yutaka Abe; Shiro Onozawa; Yasushige Komada; Yukihiro Kondo; Ryoji Kimata; Seiichiro Himeno; Mitsuo Satake
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

8.  Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.

Authors:  P S Turk; J F Belliveau; J W Darnowski; M C Weinberg; L Leenen; H J Wanebo
Journal:  Arch Surg       Date:  1993-05

9.  Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.

Authors:  S Guadagni; K R Aigner; G Palumbo; M Cantore; G Fiorentini; T Pozone; M Deraco; M Clerico; P K Chaudhuri
Journal:  J Clin Pharmacol       Date:  1998-10       Impact factor: 3.126

10.  Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer.

Authors:  H J Wanebo; J Belliveau; G Begossi; A Levy
Journal:  Colorectal Dis       Date:  2003-09       Impact factor: 3.788

View more
  1 in total

1.  Pilot study of transcatheter arterial ethanol embolization under closed renal circuit for large renal cell carcinomas.

Authors:  Satoru Murata; Hiroyuki Tajima; Shiro Onozawa; Shinichiro Kumita; Yukihiro Kondo; Kazuhiro Nomura
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 7.034

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.